Claims
- 1. A T lymphocyte, comprising:
an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte; and a chimeric receptor.
- 2. The lymphocyte of claim 1, wherein the antigen for said antigen-specific receptor comprises a viral polypeptide.
- 3. The lymphocyte of claim 2, wherein said viral polypeptide is an Epstein Barr Virus polypeptide.
- 4. The lymphocyte of claim 1, wherein said chimeric receptor further comprises an antigen-binding moiety.
- 5. The lymphocyte of claim 4, wherein said antigen-binding moiety is a single chain antibody.
- 6. The lymphocyte of claim 1, wherein said chimeric receptor is an antitumor chimeric receptor.
- 7. The lymphocyte of claim 1, wherein said antitumor chimeric receptor is 14.G2a-ζ.
- 8. The lymphocyte of claim 6, wherein said antitumor chimeric receptor is CD19 specific.
- 9. A cytotoxic T lymphocyte, comprising:
an Epstein Barr Virus-specific receptor, wherein the presence of said receptor leads to increased in vivo survival of said lymphocyte; and a 14.G2a-ζ chimeric receptor.
- 10. A cytotoxic T lymphocyte, comprising:
an Epstein Barr Virus-specific receptor, wherein the presence of said receptor leads to increased in vivo survival of said lymphocyte; and a CD 19 specific chimeric receptor.
- 11. A population of cytotoxic T lymphocytes, comprising at least one cytotoxic T lymphocyte having:
an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte; and a chimeric receptor.
- 12. The population of lymphocytes of claim 11, wherein the population comprises CD4+ T lymphocytes, CD8+ T lymphocytes, or a combination thereof.
- 13. The population of claim 11, wherein the antigen for said antigen-specific receptor comprises a viral polypeptide.
- 14. The population of claim 11, wherein said viral polypeptide is an Epstein Barr Virus polypeptide.
- 15. The population of claim 11, wherein said chimeric receptor is an antitumor chimeric receptor.
- 16. The population of claim 15, wherein said antitumor chimeric receptor is 14.G2a-ζ.
- 17. The population of claim 15, wherein said antitumor chimeric receptor is CD19 specific.
- 18. A method of enhancing activity of a chimeric T lymphocyte in an individual, comprising:
obtaining a T lymphocyte, wherein said T lymphocyte comprises
an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte; and a chimeric receptor; and administering said cell to said individual.
- 19. The method of claim 18, wherein said antigen is an Epstein-Barr Virus polypeptide.
- 20. A method of treating a disease in an individual, wherein said disease is associated with a pathogen or cell having a first antigen, comprising:
obtaining a cytotoxic T lymphocyte, wherein said lymphocyte comprises:
a receptor specific for a second antigen, wherein the presence of said second antigen-specific receptor leads to increased in vivo survival of said lymphocyte; and a chimeric receptor specific for said first antigen; and administering said T lymphocyte to said individual.
- 21. The method of claim 20, wherein said disease is cancer and said first antigen is a tumor-specific or tumor-associated antigen.
- 22. A method of treating a tumor in an individual, comprising:
obtaining a cytotoxic T lymphocyte, wherein said lymphocyte comprises:
an antigen-specific receptor, wherein the presence of said antigen-specific receptor leads to increased in vivo survival of said lymphocyte; and an antitumor chimeric receptor; and administering said T lymphocyte to said individual.
- 23. The method of claim 20 or 22, wherein said antigen is an Epstein-Barr Virus polypeptide.
- 24. The method of claim 18, 20, or 22, wherein said obtaining step is further defined as:
transfecting into a T lymphocyte a vector comprising a polynucleotide encoding said chimeric receptor.
- 25. The method of claim 24, wherein said vector is a retroviral vector.
- 26. The method of claim 22, wherein said antitumor chimeric receptor is 14.G2a-ζ.
- 27. The method of claim 22, wherein said antitumor chimeric receptor is CD-19 specific.
- 28. The method of claim 22, wherein the tumor is of neural crest origin.
- 29. The method of claim 28, wherein the tumor of neural crest origin is neuroblastoma or ganglioneuroma.
- 30. The method of claim 22, wherein the tumor is from lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, or lymphoma.
- 31. The method of claim 30, wherein the lymphoma is of B cell origin.
- 32. The method of claim 22, further comprising administering to said individual an additional cancer therapy.
- 33. The method of claim 32, wherein said additional cancer therapy is chemotherapy, radiation, surgery, or a combination thereof.
- 34. A method of preventing cancer or an intractable infection in an individual, wherein said cancer or intractable infection is associated with a pathogen or cell having a first antigen, comprising administering to an individual susceptible to said cancer or intractable infection at least one cytotoxic T lymphocyte, wherein the lymphocyte comprises:
a receptor specific for a second antigen, wherein the presence of said second antigen-specific receptor leads to increased in vivo survival of said lymphocyte; and a chimeric receptor specific for said first antigen.
- 35. The method of claim 34, wherein said second antigen is an Epstein-Barr Virus polypeptide.
- 36. The method of claim 34, wherein said cancer is of neural crest origin.
- 37. The method of claim 34, wherein said cancer is lung cancer, melanoma, breast cancer, prostate cancer, colon cancer, or lymphoma.
- 38. The method of claim 37, wherein the lymphoma is of B cell origin.
- 39. The method of claim 34, wherein said intractable infection is a viral infection or a bacterial infection.
- 40. The method of claim 38, wherein said viral infection is acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C.
- 41. A kit, housed in a suitable container, comprising:
at least one cytotoxic T lymphocyte in a pharmaceutically acceptable solution, comprising:
a chimeric receptor specific for said first antigen; and a receptor specific for a second antigen, wherein the presence of said second antigen-specific receptor leads to increased in vivo survival of said lymphocyte.
- 42. The kit of claim 41, wherein said second antigen is an Epstein-Barr Virus polypeptide.
Parent Case Info
[0001] This application claims priority to U.S. Provisional Application Serial No. 60/337,697, filed Nov. 13, 2001, and 60/337,697, filed May 30, 2002, both of which are incorporated by reference herein in their entirety.
Government Interests
[0002] The work herein was supported by grant NIH CA75014 from the United States Government. The United States Government may have certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60337697 |
Nov 2001 |
US |